Challenges and Roadmap for Treatment of Psoriasis

Abstract: Psoriasis is a chronic skin disease characterized by the provocation of immune-mediated inflammatory mediators, affecting 2 to 5% of the population worldwide regardless of age. Conventional treatment with systemic and topical drug regimens for 12 to 16 weeks can lead to side effects, safety concerns, cost issues, and the possibility of noncompliance, which may result in treatment failure. There is potential for combining phytoactives with these treatments to explore synergistic effects. A literature search on PubMed, ScienceDirect, Connected Papers, and Google Scholar was conducted, focusing on recent articles based on keywords related to “psoriasis, psoriasis pathogenesis, IL-23/IL-17, biosimilars, stem cells, herbals, phytoactives, nanoformulation, quality of life, and patient compliance.” The present study aimed to understand different psoriasis lesions and correlate the pathogenic involvement of inflammatory mediators. It also sought to explain available conventional therapies, including small molecules and phototherapy, and discuss the paradigm shift toward the development of biosimilars and stem cell therapy. Considering the chronic nature of psoriasis, reported adverse effects, and its impact on cost-effectiveness and patient quality of life, systemic and topical applications of natural products may be a better option. Natural products are well studied at the preclinical and clinical levels, targeting the cytokine IL-17/IL-23 pathways. Nanoformulation can overcome solubility and bioavailability issues and has proven effective in clinical trials. This review further elaborates on psoriasis management to address side effects, cost-effectiveness, patient compliance, and overall quality of life. Psoriasis significantly affects quality of life across demographics. Standard guidelines outline treatment protocols with appropriate follow-up and checklists for secondary infections and comorbidities. There is a need for rigorous clinical trials to establish the efficacy and safety profiles of specific phytoactives that can act as immunostimulants when combined with available treatments. Additionally, synergistic effects can be achieved, as phytoactives are known for their antioxidant and anti-inflammatory activities, which may help refine and optimize treatment protocols.

Authors

Institutions

Publication Details

Journal
Current Chemical Biology
Published
2026-03-16
DOI
https://doi.org/10.2174/0122127968394177251127093951
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Challenges and Roadmap for Treatment of Psoriasis

Monika Dharade, Asha Thomas, Tushar Nehere, P. R. Kolhe et al.
Current Chemical Biology
Psoriasis: Treatment and Pathogenesis
article

Challenges and Roadmap for Treatment of Psoriasis

Monika Dharade, Asha Thomas, Tushar Nehere, P. R. Kolhe, Lata P. Kothapalli, Avanti Todkar
article en

Abstract

Abstract: Psoriasis is a chronic skin disease characterized by the provocation of immune-mediated inflammatory mediators, affecting 2 to 5% of the population worldwide regardless of age. Conventional treatment with systemic and topical drug regimens for 12 to 16 weeks can lead to side effects, safety concerns, cost issues, and the possibility of noncompliance, which may result in treatment failure. There is potential for combining phytoactives with these treatments to explore synergistic effects. A literature search on PubMed, ScienceDirect, Connected Papers, and Google Scholar was conducted, focusing on recent articles based on keywords related to “psoriasis, psoriasis pathogenesis, IL-23/IL-17, biosimilars, stem cells, herbals, phytoactives, nanoformulation, quality of life, and patient compliance.” The present study aimed to understand different psoriasis lesions and correlate the pathogenic involvement of inflammatory mediators. It also sought to explain available conventional therapies, including small molecules and phototherapy, and discuss the paradigm shift toward the development of biosimilars and stem cell therapy. Considering the chronic nature of psoriasis, reported adverse effects, and its impact on cost-effectiveness and patient quality of life, systemic and topical applications of natural products may be a better option. Natural products are well studied at the preclinical and clinical levels, targeting the cytokine IL-17/IL-23 pathways. Nanoformulation can overcome solubility and bioavailability issues and has proven effective in clinical trials. This review further elaborates on psoriasis management to address side effects, cost-effectiveness, patient compliance, and overall quality of life. Psoriasis significantly affects quality of life across demographics. Standard guidelines outline treatment protocols with appropriate follow-up and checklists for secondary infections and comorbidities. There is a need for rigorous clinical trials to establish the efficacy and safety profiles of specific phytoactives that can act as immunostimulants when combined with available treatments. Additionally, synergistic effects can be achieved, as phytoactives are known for their antioxidant and anti-inflammatory activities, which may help refine and optimize treatment protocols.

Current Chemical BiologyVol. 20
Dr. D. Y. Patil Medical College, Hospital and Research Centre (IN)
Good health and well-being
Openalex Percentile: Top 13%
Psoriasis: Treatment and Pathogenesis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.